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LETTER TO THE EDITOR
Persistent Elevation of Fetal Hemoglobin Following Chemotherapy in
Sickle Cell Disease
To the Editor: Regulation of fetal hemoglobin (HbF) produc-
tion is complex [1]. Our experience of persistent HbF elevation
during a 7-year follow up in a child with homozygous sickle cell
disease (SCD) who underwent chemotherapy for Wilms tumor
(WT) adds to the complexity of the regulatory mechanisms in
HbF production.
An 8-year-old African–American female homozygous SCD
patient with metastatic WT was treated with vincristine, doxoru-
bicin, and actinomycin D. After 6 months of therapy, she under-
went nephrectomy; histology showed focal anaplasia. Interim, she
developed a metastatic right liver lobe nodular lesion. She then
received radiation to abdomen and lungs followed by ifosfamide,
carboplatin, and etoposide chemotherapy. The treatment was
completed in 26 months and her creatinine level remained normal.
She did not require hospitalization for SCD complications and has
had baseline hemoglobin of 9–10 g/dl. At the age of 3, her HbF
was 17.6%. Her parents do not have elevated HbF levels ruling
out hereditary persistence of HbF. Six months following treat-
ment, her HbF was 33% along with increased red blood cell
mean corpuscular volume (MCV) and mean corpuscular hemo-
globin (MCH). Despite MCV and MCH remaining stable, HbF
trended down to 20.8% (Fig. 1). This may be secondary to age-
related increase in average MCV and MCH levels in children
irrespective of the HbF. F cells shown by ﬂow cytometry were
95 and 82% at 6 months and 6 years after the completion of
chemotherapy, respectively.
Following chemotherapy, persistently high MCV has been
reported in long-term follow up; however, HbF values have not
been reported [2]. The relation between HbF and F cells in our
case was within expected age-related distribution in SCD patients
[3]. Elevation of HbF and MCV in this case is reminiscent of
stress erythropoiesis. However, increased HbF persistence has
been far long-lived in the absence of chemotherapy in contrast
to the dependence of HbF elevation on the continuous adminis-
tration of hydroxyurea in SCD. In addition to alterations in
chromatin structure or kinetics of erythroid differentiation, alter-
native mechanisms have been identiﬁed in HbF induction [4,5].
Increased HbF is seen in juvenile myelomonocytic leukemia,
which is associated with acquired mutations in the Ras/MAPK
pathway. Stem cell factor induces adult erythroid growth and HbF
production through Ras/MAPK pathway [6]. Elevated EPO is
unlikely, since increases of EPO levels are transient following
nephrectomy in kidney donors [7]. Hemoglobin levels were stable
in our case.
The current case is unique in the prolonged elevation of HbF.
Persistent chemotherapy-related bone marrow microenvironment
and cytokine milieu alterations may be an explanation. Emer-
gence of an altered stem cell population secondary to acquired
genetic or epigenetic changes resulting in a stress erythropoiesis-
like reaction might also be possible. In conclusion, prospective
evaluation of similar cases may add to our knowledge of the
regulation of HbF production.
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Fig. 1. Fetal hemoglobin (HbF), mean corpuscular volume (MCV), and mean corpuscular hemoglobin (MCH) changes over time. The
patient’s age in years is depicted on the x-axis. The values while the patient was undergoing chemotherapy were not included due to frequent
packed red blood cell transfusions.
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